Answers are grounded in this paper and cite their sources.
Shows KAT7 and KAT6A inhibition promotes myeloid differentiation in SETBP1-mutated cells, indicating a new treatment approach.
Carlson and colleagues demonstrate that SETBP1 mutations promote leukemic self-renewal by recruiting MYST acetyltransferase complexes (KAT7/KAT6A) to chromatin, where H3K14ac and H3K23ac marks are deposited on promoter sites for key stemness genes. Genetic deletion or pharmacologic inhibition of KAT7/KAT6A was shown to shut down this SETBP1-associated self-renewal program and promote myeloid differentiation of SETBP1-mutant cells. See related article by Carlson et al., p. XX .
No takes yet. Share an insight, caveat, or question.
Soto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: